Zoetis Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report; the supplied filing text does not provide clear Q4-only financial results.
Business context
Zoetis is a global animal-health company that develops, manufactures and sells medicines, vaccines, diagnostics and related products for companion animals and livestock. It reports U.S. and International operating segments. Companion-animal products generated about 65% of 2023 revenue, livestock products 34%, and contract manufacturing and human-health products about 1%. The U.S. represented 53% of revenue and International 46%.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $8.544 billion | $8.080 billion | +6% reported; +7% operational |
| Net income attributable to Zoetis | $2.344 billion | $2.114 billion | +11% |
| Diluted EPS | $5.07 | $4.49 | +13% |
| Adjusted net income (non-GAAP) | $2.457 billion | $2.297 billion | +7% |
| Operating cash flow | $2.353 billion | $1.912 billion | +$441 million |
| Capital expenditures | $732 million | $586 million | +$146 million |
| Cash and cash equivalents | $2.041 billion | $3.581 billion | -$1.540 billion |
| Long-term debt, net of discounts and issuance costs | $6.564 billion | $6.552 billion | Broadly stable |
- Revenue growth reflected approximately 5% price growth and 2% volume growth from new products; foreign exchange reduced reported growth by about 1%.
- Cost of sales was 30.0% of revenue, versus 30.4% in 2022. This implies a gross margin of approximately 70.0%, up from 69.6%. Income before taxes was 34% of revenue and net income attributable to Zoetis was 27%.
- Operating cash flow less capital expenditures was approximately $1.621 billion in 2023, calculated from the reported cash-flow and capex figures.
- Working capital was $4.454 billion and the current ratio was 3.36:1 at year-end. Cash declined mainly amid financing outflows, including repayment of $1.35 billion of notes, $1.092 billion of treasury-share purchases and $692 million of cash dividends.
- Gross principal debt was $6.65 billion. The company had no borrowings under its $1.0 billion revolving facility or commercial-paper program at year-end; it reported compliance with debt covenants.
Material changes versus 2022
- Companion-animal revenue rose 7% to $5.576 billion; livestock revenue rose 4% to $2.890 billion. U.S. and International segment revenue each increased 6% reported.
- Growth was led in part by Librela and Solensia, monoclonal-antibody therapies for osteoarthritis pain, and by parasiticides and dermatology products. U.S. livestock growth in cattle and poultry was partly offset by lower swine sales.
- International operational revenue grew 9%, but foreign exchange reduced reported International revenue by approximately $116 million.
- R&D expense increased 14% to $614 million, reflecting compensation, project investment and other operating costs. SG&A rose 7% to $2.151 billion.
- Other income/deductions shifted to $159 million of net income from $40 million of net deductions. Key contributors included a $101 million pretax gain on selling a majority interest in the pet-insurance business, higher interest income and a royalty settlement relating to prior periods.
- Capital expenditures increased to $732 million. Zoetis also acquired PetMedix and adivo and purchased a manufacturing site outside Atlanta, with commercial production planned for the future.
Outlook, commentary, risks and unusual items
- The filing does not provide a clear quantitative revenue or earnings forecast. Management stated that cash, operating cash flows and available financing are expected to support cash needs for the next twelve months and beyond, subject to business conditions.
- Management’s strategy emphasizes product innovation and lifecycle extensions, customer experience, digital and data capabilities, talent, sustainability and operating efficiency. The company reported more than 300 R&D programs and R&D expense of $614 million.
- Product and patent concentration is material: the five largest product lines generated about 37% of revenue and the ten largest about 49%. Simparica/Simparica Trio and Apoquel/Apoquel Chewable contributed about 13% and 10%, respectively.
- Generic competition has pressured Draxxin and other products. The company reported U.S. Draxxin sales down 47% since generic competition began in 2021 and said additional declines are expected. It did not anticipate U.S. generic Excede entry before July 2024.
- Other principal risks include product safety or quality issues, supply interruptions and capacity constraints, animal-disease outbreaks, foreign-exchange volatility, customer and distributor consolidation, regulatory changes (including restrictions on livestock antibacterials), economic and geopolitical conditions, cyber and privacy threats, and climate and environmental risks.
- Legal and regulatory matters include an appeal concerning the EU’s Belgium excess-profit tax state-aid decision and an environmental matter in Brazil. Management said ordinary-course proceedings were not expected to have a material adverse effect on consolidated results, financial condition or cash flows, but noted outcomes remain uncertain and excess reasonably possible losses could not be estimated. OFAC issued a 2023 No Action letter concerning potentially noncompliant Iran-related transactions by an acquired business; the Department of Justice had not responded as of the filing.
- Auditors issued an unqualified opinion on the financial statements and internal control over financial reporting. The filing identifies U.S. rebates accruals and unrecognized tax benefits as critical audit matters.
Important facts for investors to verify
- Whether growth and margins remain supported by pricing and new products, and how demand develops for Librela, Solensia and other recently launched products.
- Revenue exposure to the leading product lines, including the timing and effect of generic entries and patent expirations.
- Cash generation versus elevated capital spending, share repurchases and dividends; also monitor cash balances, debt maturities and interest costs.
- International growth excluding foreign exchange, particularly in markets affected by currency movements and economic or regulatory uncertainty.
- Progress of acquisitions and R&D programs, including the commercial potential and impairment risk of acquired in-process research and development assets.
- Updates on the disclosed tax, litigation and environmental matters, and the assumptions underlying rebate accruals and uncertain tax positions.